Completed
PHASE1
INTERVENTIONAL
NCT02553603
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study is examining the effects of growth hormone releasing hormone (GHRH) on mild cognitive impairment (MCI). GHRH will be given at a dose of 1mg/day for 10 weeks to subjects with MCI as well as healthy controls.
Detailed Description
Subjects with MCI as well as healthy controls will be given GHRH at a dose of 1mg/day for 10 weeks. This study is designed to investigate the effects of GHRH on the following things: 1) cognitive function as measured by our neuropsychologist with a series of short tests; 2) brain activity as measured by fMRI 3) lean and fat mass of your body as measured by DEXA; 4) physical function as measured by a walking test.
Interventions
Name:
Growth Hormone Releasing Hormone (GHRH)
Type:
DRUG
Description:
Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
Name:
Placebo Growth Hormone Releasing Hormone
Type:
DRUG
Description:
Placebo GHRH to be given once daily for 10 weeks
Primary Outcomes
Measure:
Cognitive Function measured by SLUMS
TimeFrame:
10 weeks
Description:
Cognitive function at 10 weeks measured by the St Louis University Mental Status (SLUMS)
Measure:
Brain Perfusion measured by fMRI
TimeFrame:
10 weeks
Description:
Brain Perfusion at 10 week measured by MRI
Measure:
Brain Morphology measured by MRI
TimeFrame:
10 weeks
Description:
Brain Morphology at 10 weeks measured by MRI
Trial Information
NCT ID
NCT02553603
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
The University of Texas Medical Branch, Galveston
Last Updated
December 15, 2025